Patents by Inventor David J. Bearss

David J. Bearss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING
    Publication number: 20210052568
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Application
    Filed: March 10, 2020
    Publication date: February 25, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, David J. Bearss
  • Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
    Publication number: 20210000825
    Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, X2, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 2, 2020
    Publication date: January 7, 2021
    Inventors: Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott, David J. Bearss
  • Combination therapies for treatment of cancer
    Patent number: 10835537
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 17, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • ALK5 INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20200323851
    Abstract: Described herein are methods for treating ALK5-mediated disease including myelodysplastic syndrome (MDS), anemia and anemia of chronic disease. Also provided are methods of inhibiting ALK5.
    Type: Application
    Filed: January 10, 2020
    Publication date: October 15, 2020
    Inventors: David J. BEARSS, Steven L. WARNER
  • METHODS TO TARGET TRANSCRIPTIONAL CONTROL AT SUPER-ENHANCER REGIONS
    Publication number: 20200316084
    Abstract: Methods for targeting super enhancers by administration of two or more therapeutic agents are provided. The methods are useful for treatment of various super-enhancer-mediated diseases and conditions, such as cancer. Compositions comprising the two or more therapeutic agents are also provided.
    Type: Application
    Filed: December 30, 2019
    Publication date: October 8, 2020
    Inventors: Steven L. WARNER, David J. BEARSS
  • COMPOSITIONS COMPRISING PKM2 MODULATORS AND METHODS OF TREATMENT USING THE SAME
    Publication number: 20200297698
    Abstract: A compound of Structure (I): or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 24, 2020
    Inventors: Steven L. WARNER, David J. BEARSS, Jason Marc FOULKS
  • METHODS FOR TREATING CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER
    Publication number: 20200281949
    Abstract: Methods of treating castration-resistant and castration-sensitive prostate cancer using a compound having the following structure (I): or a pharmaceutically acceptable salt or zwitterionic form thereof, are provided.
    Type: Application
    Filed: December 6, 2019
    Publication date: September 10, 2020
    Inventors: Steven L. WARNER, David J. BEARSS, Stephen Patrick ANTHONY, Michael Vincent MCCULLAR
  • TREATMENT REGIMEN FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 INHIBITOR ALVOCIDIB
    Publication number: 20200276215
    Abstract: Methods for treating BCL-2 inhibitor-resistant cancer in subjects using an MCL-1 inhibitor as well as compositions associated with the same are disclosed.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 3, 2020
    Inventors: David J. BEARSS, Adam SIDDIQUI-JAIN, Clifford J. WHATCOTT, Steven L. WARNER
  • CYCLIN-DEPENDENT KINASE INHIBITORS IN COMBINATION WITH ANTHRACYCLINES FOR TREATMENT OF CANCER
    Publication number: 20200276174
    Abstract: Methods for treating cancer by administration of two or more therapeutic agents are provided. The two or more therapeutic agents include a cyclin-dependent kinase inhibitor (e.g., alvocidib) and an anthracycline (e.g., daunorubicin or idarubicin). Kits comprising the two or more therapeutic agents that can be used to perform such methods are also provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: September 3, 2020
    Inventors: David J. BEARSS, Steven L. WARNER, Clifford J. WHATCOTT
  • JAK1 and ALK2 inhibitors and methods for their use
    Patent number: 10752594
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 25, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER
    Publication number: 20200237766
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a PKM2 activator and an anti-cancer drug having a mechanism of action that increases production of reactive oxygen species in cancer cells to a patient in need thereof.
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Inventors: Adam SIDDIQUI-JAIN, Peter W. PETERSON, Clifford J. WHATCOTT, David J. BEARSS, Steven L. WARNER
  • COMBINATION THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20200215071
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase S inhibitor to a mammal in need thereof.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Applicant: TOLERO PHARMACEUTICALS, INC.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • PROFILING PEPTIDES AND METHODS FOR SENSITIVITY PROFILING
    Publication number: 20200200737
    Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
    Type: Application
    Filed: August 20, 2019
    Publication date: June 25, 2020
    Applicant: Tolero Pharmaceuticals, Inc.
    Inventors: David J. BEARSS, Adam SIDDIQUI-JAIN, Clifford J. WHATCOTT, Peter W. PETERSON, Steven L. WARNER, Lars MOURITSEN
  • Combination therapies for treatment of cancer
    Patent number: 10682356
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: June 16, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY
    Publication number: 20200131210
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Application
    Filed: December 26, 2019
    Publication date: April 30, 2020
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Predicting response to alvocidib by mitochondrial profiling
    Patent number: 10624880
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: April 21, 2020
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Steven L. Warner, David J. Bearss
  • METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
    Publication number: 20200085823
    Abstract: Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).
    Type: Application
    Filed: July 26, 2019
    Publication date: March 19, 2020
    Inventors: Steven L. Warner, David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony, Paul Flynn, Yuji Fujiwara, Yuka Arikawa
  • Combination therapies for treatment of cancer
    Patent number: 10568887
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 25, 2020
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • COMBINATION THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20200054642
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • Alvocidib prodrugs having increased bioavailability
    Patent number: 10562925
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 18, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Adam Siddiqui-Jain, David J. Bearss